Printer Friendly

INTERNATIONAL MUREX PROMOTES J. DAVID THOLEN TO CHIEF EXECUTIVE OFFICER

 NORCROSS, Ga., Nov. 2 /PRNewswire/ -- International Murex Technologies Corporation (AMEX, TSE: MXX) today announced the promotion of J. David Tholen, 49, to the position of chief executive officer and president. Formerly of Abbott Laboratories, Tholen has held the positions of chief operating officer and president at International Murex since June. Tholen is also a member of International Murex's board of directors. C. Robert Cusick, previously chief executive officer and vice chairman, will continue as vice chairman and as a member of the Executive Committee of the board of directors.
 "Over the past 20 months, management has concentrated on transforming International Murex from a small research firm to a major international diagnostic products company, and that objective has been successfully met," said F. Michael P. Warren, International Murex chairman. "We are now charting the next phase of the company's future growth, and we believe it will be an advantage to have Dave Tholen take a leadership role in both strategic and operating issues."
 Effective immediately, Tholen assumes responsibility for the overall direction of the company's operations, including international sales, marketing, product development, strategic planning and finance. Cusick will concentrate primarily on identifying and implementing acquisition opportunities and financing options, and corporate outreach to the financial community.
 Since joining International Murex in June 1993, Tholen has improved many aspects of the company's operations, setting entrepreneurial objectives at each level of management, establishing new facilities, and upgrading the company's information management systems and human resource programs. He has more than 20 years of experience in medical diagnostics with Abbott Laboratories, where he most recently served as divisional vice president and general manager in its Diagnostic Division. At Abbott, he had overall profit and loss responsibility, including oversight of the worldwide research and development, marketing, manufacturing and technical product support operations for one of its sectors. Previously, he directed all marketing and strategic planning activities for Abbott Diagnostics for Europe, Africa, and the Middle East.
 Cusick has served as chief executive officer of International Murex since 1990. During that time, he successfully raised more than $70 million in financing for the company, implemented the 1992 acquisition by International Murex of Wellcome Diagnostics, and oversaw the integration and restructuring of that operation.
 International Murex Technologies Corporation is a medical diagnostic products company dedicated to the research, manufacture and marketing of products for the detection, monitoring and screening of infectious diseases and other medical conditions. The company manufactures and markets on a worldwide basis more than 600 products.
 -0- 11/2/93
 /CONTACT: Marcia M. Young, director of corporate communications of International Murex Technologies, 800-322-1332 or 404-662-0660; Ellen T. Corliss, of Feinstein Partners 617-577-8110 (media contact) for International Murex Technolgies/
 (MXX)


CO: International Murex Technologies Corporation ST: Georgia IN: MTC SU: PER

DJ-CM -- NE005 -- 9582 11/02/93 10:29 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 2, 1993
Words:465
Previous Article:COMMUNITY FIRST BANKSHARES TO ACQUIRE BANK IN WISCONSIN
Next Article:BUTLER INTERNATIONAL REPORTS THIRD QUARTER -- NINE MONTHS, 1993 RESULTS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters